NASDAQ: GPATGP Act III Acquisition Corp Stock
$10.49+0.00 (+0%)
Updated May 16, 2025
GPAT Price
$10.49
Fair Value Price
N/A
Market Cap
$376.80M
52 Week Low
$9.98
52 Week High
$10.49
P/E
29.96x
P/B
-26.66x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$11.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.05
Operating Cash Flow
-$689k
Beta
0.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GPAT Overview
GP-Act III Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as GP Investments Acquisition Corp. II and changed its name to GP-Act III Acquisition Corp. in November 2020. GP-Act III Acquisition Corp. was incorporated in 2020 and is based in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GPAT's potential to beat the market
- GPAT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Shell Company
Industry Rating
F
GPAT
RankedUnranked of 23
RankedUnranked of 23
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.03 | C | |
| $10.40 | C | |
| $10.45 | C |
Be the first to know about important GPAT news, forecast changes, insider trades & much more!
GPAT News
Overview
Due Diligence Score
–
Industry Average (6)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GPAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GPAT is poor value based on its earnings relative to its share price (29.96x), compared to the US market average (25.95x)
P/E vs Market Valuation
GPAT is poor value based on its earnings relative to its share price (29.96x), compared to the US Shell Companies industry average (19.62x)
P/E vs Industry Valuation
GPAT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more GPAT due diligence checks available for Premium users.
Valuation
GPAT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
29.96x
Industry
19.62x
Market
25.95x
GPAT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GPAT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
GPAT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-26.66x
Industry
-49.27x
GPAT's financial health
Profit margin
Revenue
$0.0
Net Income
$2.9M
Profit Margin
0%
GPAT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$300.5M
Liabilities
$14.8M
Debt to equity
-1.05
GPAT's short-term liabilities ($738.52k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GPAT's long-term liabilities ($14.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GPAT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GPAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$151.9k
Investing
$0.0
Financing
$44.9k
GPAT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GPAT vs Shell Company Stocks
Act III Acquisition Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.